Unlocking the
potential of HPAPIs
With the rise of highly targeted therapeutics and complex new chemical entities (NCEs), the global demand for highly potent APIs (HPAPIs) continues to climb. HPAPIs are widely sought after for their ability to offer more targeted treatments at lower doses and with fewer side effects.1 As the number of highly potent molecules in development rises, so does the demand for an outsourced HPAPI solution provider.
Read on to explore the growth of highly potent molecules and explore key considerations to unlock their full potential in your organisation.
25%
of drugs are considered highly potent today.2
Why the growth?
Several key factors have contributed to the growth of outsourced HPAPI development and manufacture.
Targeted therapeutics on the rise.
60% of oncology drugs today involve highly potent intermediates.3
Enhanced toxicological assessments and improved health and safety standards.
APIs with an 8-hour average OEL of <10 µg/m3 generally call for contained processing.4
High cost of entry and specialised equipment.
50% of biopharmaceutical professionals expressed plans to outsource HPAPI services.7
Poll
Loading ...Choosing a
potential partner
Key factors for success when making your HPAPI outsourcing decision
Research estimates that there are roughly 96 CDMOs representing 130 facilities that deliver HPAPI services.7 But not all vendors are created equal. The decision to outsource HPAPI services is an important one, and selecting the right partner is essential.
Click on the five characteristics below to shape your search for a partner that will help you put the potential of HPAPIs to work.
Poll
Loading ...Maximising the potential with Sterling
Delivering world-class HPAPI solutions
At Sterling, we understand the challenges you face when searching for the right small molecule HPAPI partner. Through our world-class HPAPI facilities, specialised processes, expert personnel, and uniquely collaborative approach, we address all of the characteristics that are key to maximising the potential of your HPAPI programmes.
Explore our cGMP manufacturing suites to learn more about our multi-layered approach to containment, and our dedicated HPAPI teams and processes.
- Specialised teamsOur dedicated HPAPI team, composed of some of the industry’s leading experts in handling highly potent compounds, undergoes comprehensive and specific training on control, containment, and cleaning.
- Process designLeveraging our deep process engineering and optimisation expertise, we work with you to combine HPAPI-specific processes with best practices in small molecule API development and manufacture for optimal quality, safety, and efficiency.
- Flexible assetsOur flexible asset configuration enables us to adjust our equipment and processes as needed to account for the specific requirements of your programme.
- Multi-layered containment approachWe have a containment approach that safeguards processes and personnel through concentric layers of protection.
- Process downflow boothsShould primary containment fail, they are fully enclosed in downflow booths with unidirectional airflow to direct any potentially hazardous materials away from operators’ breathing space and the wider facility.
- Advanced engineering controlsPrimary controls within the equipment itself act as a first layer of protection, supporting containment of potentially hazardous particles at the nanogram level.
- Isolated cGMP suitesIn the unlikely event that anything manages to pass through the first two safeguards, airlocks within the suites themselves prevent it from migrating to the wider facility.
- Personal protective equipmentOur team members are equipped with PPE to protect them from potentially hazardous materials. Our isolation suites include designated areas for gowning and de-gowning, as well as misting showers for complete migration control.
Are you ready to maximise the potential of HPAPIs in your organisation?
Request more information by filling out the form below.
- Patnaik, T. HPAPI: When Less is More, 2011. Contract Pharma. https://www.contractpharma.com/issues/2011-09/view_features/hpapi-when-less-is-more/ (accessed Dec 14, 2020).
- Choosing the right CMO for outsourced work with APIs, 2015. Manufacturing Chemist. https://manufacturingchemist.com/news/article_page/Choosing_the_right_CMO_for_outsourced_work_with_HPAPIs/112307 (accessed Dec 14, 2020).
- Vatsa, K. Trends in CMO Market of High Potency Drugs, 2019. American Pharmaceutical Review. https://www.americanpharmaceuticalreview.com/Featured-Articles/363901-Trends-in-CMO-Market-of-High-Potency-Drugs/ (accessed Dec 14, 2020).
- Pavlovich, J. Classifying Potent and Highly Potent Molecules. Pharmaceutical Technology [Online] 2018, 2018 Supplement, s18-s20, s33. https://www.pharmtech.com/view/classifying-potent-and-highly-potent-molecules (accessed Dec 14, 2020).
- Haigney, S. HPAPI Capacity Challenges. Pharmaceutical Technology [Online] 2019, 2019 Supplement, s6-s10. https://www.pharmtech.com/view/hpapi-capacity-challenges (accessed Dec 14, 2020).
- Tiene, G. Targeted, Highly Potent Therapies: Big Growth Driver for the CDMO Market is Here…, 2016. Pharma’s Almanac. https://www.pharmasalmanac.com/articles/targeted-highly-potent-therapies-big-growth-driver-for-the-cdmo-market-le-here (accessed Dec 14, 2020).
- Munk, S. High Potency API Market Trends, 2016. Contract Pharma. https://www.contractpharma.com/issues/2016-09-01/view_features/high-potency-api-market-trends/ (accessed Dec 14, 2020).
